<DOC>
	<DOCNO>NCT02894723</DOCNO>
	<brief_summary>Essential Hypertension characterize endothelial dysfunction due reduce nitric oxide ( NO ) bioavailability . Impairment nitric oxide-mediated vasodilatation human brachial , coronary , renal artery demonstrate patient essential hypertension . Administration L-arginine , NO substrate yeld controversial result . The purpose present study , double blind match age , sex body mass index ( BMI ) , assess efficacy L-arginine treatment blood pressure ( BP ) control arterial stiffness patient stage1 hypertension .</brief_summary>
	<brief_title>L-arginine Treatment Mild Hypertension</brief_title>
	<detailed_description>Scientific background Essential Hypertension characterize endothelial dysfunction impaired vasorelaxation . Reduced nitric oxide bioavailability , consider hallmark endothelial dysfunction , play important role mediate blood pressure elevation . Accumulating evidence demonstrate critical role nitric oxide blood pressure regulation . Released endothelial cell , nitric oxide increase 30,50-cyclic-guanosine monophosphate ( cGMP ) production subsequent cGMP-dependent protein kinase ( PKG ) activation underneath vascular smooth muscle cell ( VSMCs ) , result vasodilatation . The investigator others show inhibition NO synthesis increase blood pressure normal pregnant rat different animal model . In vivo study confirm essential role nitric oxide vasorelaxation large human artery . Impairment nitric oxide-mediated vasodilatation brachial , coronary , renal artery demonstrate patient essential hypertension . Several mechanism find responsible nitric oxide deficiency hypertension . One deficit NO substrate , L-arginine . L-arginine transport impair hypertensive normotensive patient genetic background essential hypertension , offspring essential hypertensive patient characterize reduced response acetylcholine link defect nitric oxide pathway . These data represent link L-arginine onset essential hypertension . The Km endothelial nitric oxide synthase L-arginine 3mmol/l , concentration plasma L-arginine rarely fall 60mmol/l pathological condition . An elevation asymmetric dimethylarginine ( ADMA , endogenous NO competitive inhibitor ) level may explain ' L-arginine paradox ' . The administration excess exogenous L-arginine displaces competitive inhibitor , improve intracellular transport amino acid , restore NO production physiological level . In fact L-arginine supplementation improve endothelial dysfunction hypertension . Administration L arginine human show uniform blood pressure response . A meta-analysis publish 2011 able find 11 article deal l-arginine administration blood pressure . The population study heterogeneous . Compared placebo , oral L-arginine intervention associate average net change range −23.0 2.8 mm Hg SBP −11.0 1.0 mm Hg diastolic BP . Most trial show intervention-related trend toward BP reduction , reach statistical significance . Endothelial dysfunction lead increase arterial stiffness , know marker increase cardiovascular morbidity mortality . Arterial stiffness measure non invasive methodology , e.g . ; measure carotid-femoral pulse wave velocity , augmentation index , aortic pulse pressure aortic systolic blood pressure . Whether administration l-arginine improve arterial stiffness patient mild hypertension know . Arginoline dietary supplement contain L-arginine concentration 5 g/L . It possible dilute water take chill . It produce Pharmayeda , Israeli industry . Clinical observational study [ personal communication ] show dose 60 ml\day [ 10 gr l-arginine ] flow mediate vasodilation improves , suggest increase nitric oxide function . Methods Office Blood Pressure ( OBP ) measurement : OBP measure Suntech 247 digital automate device . BP determine 3 time one min . interval . The mean second third measurement note OBP visit . ABPM : 24 hour ABPM perform Oscar 2 ABPM device SunTech Medical . The Oscar 2 ABPM device clinically validate 3 internationally recognize protocol ( British Heart Society , American Society Hypertension Association Advancement Medical Instrumentation ) . Blood pressure measure 20 min . interval day time 30 min . interval night time . The patient request fill diary activity ABPM study , include subjective evaluation sleep quality . Measurement arterial stiffness : The SphygmoCor X-CEL System ( AtCor Medical , Sydney , Australia ) use . The system derive ( non invasively ) ascend aortic pressure waveform brachial waveform use validate generalised transfer function . The SphygmoCor X-CEL system measure carotid-femoral pulse wave velocity ( PWV ) , speed arterial pressure waveform travel descend aorta femoral artery , detect simultaneously measure carotid femoral arterial pulse . Design The study match double blind study experimental group placebo group . As number group small ( 20 group ) patient match accord age , sex BMI recruitment phase , order get comparable group . The principal investigator responsible matching . The experimental group receive arginoline 30 ml twice day placebo group receive placebo schedule Visits : Week -2 : Sign inform consent Office BP . Physical examination . BMI . Blood exam : Hemoglobin ( g % ) , urea ( mg % ) , creatinine ( mg % ) , Natrium ( mEq/l ) , Potassium ( mEq/l ) , alanine transaminase ( ALT ) , Aspartate aminotransferase ( AST ) , gamma-glutamyl transpeptidase ( GGT ) , glucose , cholesterol triglyceride . lipid profile . Urine analysis : microalbuminuria ( morning spot ) All patient receive booklet detail information healthy life style recommendation lower blood pressure . Hypertensive patient monotherapy stop treatment . Week 0 ABPM Measurement Central aortic blood pressure arterial stiffness Blind group allocation ( experimental placebo group ) . Week 2 Office BP measurement . Week 4 Office BP measurement Week 6 Office BP measurement Week 8 : ABPM , office BP , Repeat blood urine exam detail week -2 . Measurement Central aortic blood pressure Arterial stiffness Statistical evaluation Will do use IBM SPSS statistical software . Pi &lt; 0.05 consider significative</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Inclusion criterion : Stage 1 hypertensive patient , office Systolic BP 140159 mmHg and/or diastolic BP 999 mmHg , untreated treat monotherapy . None two risk factor [ smoking , hyperlipidemia , obesity , family history cardiovascular disease ] . BMI 25 32 . Twenty hour ambulatory blood pressure monitor ( ABPM ) mean Systolic BP 130149 mmHg and/or mean Diastolic BP 8089 mmHg . Exclusion criterion : Use drug may affect nitric oxide synthesis and/or blood pressure value ( nitrate , antihypertensive drug , non steroidal antiinflammatory drug , steroid , pseudoephedrine ) . Diabetes mellitus . Renal failure define estimate glomerular filtration rate ( eGFR ) less 60 ml/min , use Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) formula . A previous diagnosis ischemic heart disease , Transient ischemic attack ( TIA ) , Stroke peripheral arterial disease . Patients recurrent herpes woman plan pregnancy next year . Cancer treat radiotherapy chemotherapy last year .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hypertension ,</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>L-Arginine</keyword>
	<keyword>Arterial Stiffness</keyword>
	<keyword>Ambulatory blood pressure measurement</keyword>
</DOC>